Exhaled Breath Particles in Lung Transplantation
Launched by LUND UNIVERSITY HOSPITAL · May 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how exhaled breath particles (tiny particles in the air we breathe out) can help detect lung transplant rejection early. Lung transplantation is a vital treatment for patients with severe lung disease, but unfortunately, survival rates are lower compared to other organ transplants. Early detection of rejection is crucial because it can lead to better treatment options and improved survival rates. The researchers want to see if the patterns and composition of these exhaled particles can reveal important information about a patient’s lung health, particularly in recognizing problems like primary graft dysfunction (PGD) and chronic rejection.
To take part in this study, participants must be patients who have received a lung transplant at Skåne University Hospital in Lund. There are no specific exclusions, so anyone meeting this criterion can join. Participants will provide samples of their exhaled breath, and the researchers will analyze these samples to find patterns that could help identify issues early on. This research aims to improve monitoring and treatment for lung transplant patients, making it an important step in enhancing their care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have undergone LTx at Skåne University Hospital, SUS Lund
- Exclusion Criteria:
- • None
About Lund University Hospital
Lund University Hospital, affiliated with Lund University in Sweden, is a leading institution in medical research and clinical trials. Renowned for its commitment to advancing healthcare through innovative research, the hospital integrates clinical practice with academic excellence. As a sponsor of clinical trials, Lund University Hospital focuses on a wide range of therapeutic areas, striving to improve patient outcomes by rigorously evaluating new treatments and interventions. With a multidisciplinary team of expert researchers and clinicians, the hospital emphasizes ethical standards, patient safety, and scientific integrity in all its studies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, Skåne Län, Sweden
Lund, , Sweden
Patients applied
Trial Officials
Sandra Lindstedt, MD, PhD
Principal Investigator
Region Skåne, Lund University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials